Filing Details

Accession Number:
0001209191-12-059070
Form Type:
4
Zero Holdings:
No
Publication Time:
2012-12-21 16:32:38
Reporting Period:
2012-12-20
Filing Date:
2012-12-21
Accepted Time:
2012-12-21 16:32:38
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1009356 Salix Pharmaceuticals Ltd SLXP Pharmaceutical Preparations (2834) 943267443
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1212670 J Carolyn Logan 8510 Colonnade Center Drive
Raleigh NC 27615
President & Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2012-12-20 33,750 $7.60 660,881 No 4 M Direct
Common Stock Disposition 2012-12-20 25,000 $42.27 635,881 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Option to Buy Common Stock Disposition 2012-12-20 33,750 $0.00 33,750 $7.60
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2013-07-24 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 400,000 Indirect by GRAT
Reported Derivative Holdings
Sec. Name Sec. Type Price Date Expiration Date Amount Remaning Holdings Nature of Ownership
Common Stock Option to Buy Common Stock $17.63 2015-06-09 44,000 44,000 Direct
Common Stock Option to Buy Common Stock $18.87 2014-06-17 33,750 33,750 Direct
Common Stock Option to Buy Common Stock $18.87 2014-06-17 65,625 65,625 Direct
Expiration Date Amount Remaning Holdings Nature of Ownership
2015-06-09 44,000 44,000 Direct
2014-06-17 33,750 33,750 Direct
2014-06-17 65,625 65,625 Direct
Footnotes
  1. This sale was pursuant to a Rule 10b5-1 Sales Plan dated December 4, 2012, which is intended to comply with Rule 10b5-1.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.14 to $42.51, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.
  3. Options are 100% vested.